Business Context and Reporting Period
This filing is a Form 10-Q for AmerisourceBergen Corporation (note: the metadata references "Cencora," but the filing text identifies the registrant as AmerisourceBergen Corporation) for the quarterly period ended December 31, 2008. The company operates as a pharmaceutical services provider, aggregating its operations into one reportable segment: Pharmaceutical Distribution. This segment includes drug distribution (ABDC), specialty group services (ABSG), and packaging (ABPG). The company completed the divestiture of its workers' compensation business, PMSI, in October 2008, classifying it as discontinued operations.
Key Financial Metrics
| Metric | Q4 2008 | Q4 2007 |
|---|---|---|
| Total Revenue | $17.34 billion | $17.28 billion |
| Gross Profit | $489.8 million | $484.2 million |
| Gross Margin | 2.83% | 2.80% |
| Operating Income | $197.9 million | $192.6 million |
| Net Income | $111.1 million | $109.8 million |
| Diluted EPS | $0.72 | $0.66 |
| Cash and Equivalents | $470.9 million | $524.1 million |
| Total Debt (Outstanding) | $1.19 billion | $1.19 billion |
| Operating Cash Flow | ($304.4 million) used | ($101.0 million) used |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 0.3% year-over-year. This was driven by a 5% increase in the Specialty Group (ABSG) offset by a 0.5% decline in the Drug Corporation (ABDC). The ABDC decline was primarily due to the loss of a national retail drug chain customer (approx. $3.0 billion annualized) effective July 2008, partially offset by an 8% increase in sales to institutional customers.
- Profitability: Operating income increased 3% to $197.9 million. Gross profit margin expanded 3 basis points to 2.83%, aided by generic program growth and fee-for-service agreements, though partially offset by a $12.7 million loss on the influenza vaccine program (including a $15.5 million inventory write-down).
- Cash Flow: Operating cash flow usage increased significantly to $304.4 million (compared to $101.0 million in the prior year). This was primarily due to a $768.9 million increase in merchandise inventories and an $80.1 million increase in accounts receivable, offset by a $366.6 million increase in accounts payable.
- Discontinued Operations: The company recorded a loss of $1.5 million from discontinued operations (PMSI) in Q4 2008, compared to income of $1.4 million in Q4 2007.
Guidance, Outlook, and Risks
- Revenue Guidance: Management expects total revenue growth in fiscal 2009 to be between 1% and 3%. This outlook assumes market growth of 1-2% and strong institutional customer growth, offset by the loss of the retail chain business.
- Anemia Drug Risks: Sales of anemia-related products (approx. 5.5% of revenue) declined 11% year-over-year, with oncology-related anemia sales down 27%. Management expects further declines in fiscal 2009 due to FDA safety labeling requirements, restrictive Medicare reimbursement policies, and changes in clinical guidelines.
- Liquidity and Credit Markets: The company faces risks from credit market volatility. Availability under its Multi-Currency Revolving Credit Facility was reduced by $55 million due to the bankruptcy of Lehman Commercial Paper, Inc. The company also faces the renewal of its $975 million receivables securitization facility in 2009, which may occur at higher interest rates.
- Capital Allocation: The company authorized a new $500 million share repurchase program in November 2008. It expects to purchase approximately $350 million of stock in fiscal 2009. The quarterly dividend was increased by 33% to $0.10 per share.
- Legal Contingencies: Significant pending matters include the RxUSA lawsuit (counterclaims alleging $61 million in damages) and the Bergen Brunswig executive litigation (potential liability for supplemental retirement benefits).
Investor Verification Checklist
- Customer Concentration: Verify the impact of the lost $3.0 billion retail chain business and the reliance on the "largest customer" for institutional growth.
- Inventory Levels: Confirm the rationale for the $769 million increase in inventory and the associated cash flow strain, particularly given the economic downturn.
- Anemia Drug Exposure: Assess the long-term revenue impact of declining anemia drug sales and potential further regulatory restrictions by the FDA and CMS.
- Debt Renewal: Monitor the renewal terms of the $975 million receivables securitization facility expiring in 2009 and the potential for higher borrowing costs.
- Legal Reserves: Review the status of the RxUSA and Bergen Brunswig litigation to ensure adequate reserves are maintained against potential adverse judgments.